In line with this observation, recent evidence has shown that a PPARδ agonist inhibited aortic inflammation and attenuated the progression of pre-established atherosclerosis through reduction of plasma lipids, particularly very low-density and intermediate-density lipoproteins [32]. This evidence concerns the gene PPARD and atherosclerosis.